Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001567160-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-17 | 2026-02-12+ | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +9,714 | 146.3K | +7% | $0 |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | Gano Kyle | CEO, Dir | F - Tax | $123.87 | -10.6K | 144.0K | -7% | -$1.32M |
| D | 2026-02-17 | 2026-02-13 | NBIX | Gano Kyle | CEO, Dir | A - Grant | $0.00 | +9,968 | 156.2K | +7% | $0 |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | -9,714 | 2,566 | -79% | $0 |
| DM | 2026-02-17 | 2026-02-13 | NBIX | Gano Kyle | CEO, Dir | A - Grant | $0.00 | +135.0K | 20.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | M | A | 4,907 | $0.00 | 146,661 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-13 | F | D | 5,378 | $124.12 | 150,815 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 3 | Common | Common Stock | 2026-02-13 | A | A | 9,968 | $0.00 | 156,193 | D | — | — | (F2) On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. |
| 4 | Common | Common Stock | 2026-02-13 | F | D | 1,385 | $124.12 | 146,225 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 5 | Common | Common Stock | 2026-02-13 | M | A | 2,566 | $0.00 | 147,610 | D | — | — | |
| 6 | Common | Common Stock | 2026-02-13 | F | D | 1,210 | $124.12 | 145,044 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 7 | Common | Common Stock | 2026-02-13 | M | A | 2,241 | $0.00 | 146,254 | D | — | — | |
| 8 | Common | Common Stock | 2026-02-12 | F | D | 2,648 | $123.10 | 144,013 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 9 | Derivative | Restricted Stock Unit | 2026-02-12 | M | D | 4,907 | $0.00 | 14,721 | D | — · — to — | 4,907 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F4) This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award. |
| 10 | Derivative | Restricted Stock Unit | 2026-02-13 | M | D | 2,241 | $0.00 | 4,484 | D | — · — to — | 2,241 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. |
| 11 | Derivative | Restricted Stock Unit | 2026-02-13 | M | D | 2,566 | $0.00 | 2,566 | D | — · — to — | 2,566 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F6) This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. |
| 12 | Derivative | Stock Option | 2026-02-13 | A | A | 114,830 | $0.00 | 114,830 | D | $124.12 · — to 2036-02-13 | 114,830 Common Stock | (F7) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| 13 | Derivative | Restricted Stock Unit | 2026-02-13 | A | A | 20,142 | $0.00 | 20,142 | D | — · — to — | 20,142 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F8) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. |